Aktis Oncology (NASDAQ:AKTS) Rating Increased to Strong-Buy at BMO Capital Markets

BMO Capital Markets upgraded shares of Aktis Oncology (NASDAQ:AKTS) to a strong-buy rating in a research note released on Tuesday, Marketbeat reports.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. JPMorgan Chase & Co. increased their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. Raymond James Financial assumed coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective on the stock. Wedbush began coverage on Aktis Oncology in a research report on Wednesday. They set an “outperform” rating and a $35.00 target price for the company. Finally, Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Aktis Oncology has an average rating of “Buy” and an average price target of $35.00.

Aktis Oncology Stock Up 0.1%

AKTS stock opened at $25.02 on Tuesday. The company has a 50 day moving average of $25.35 and a two-hundred day moving average of $21.25. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19. The company has a market cap of $1.34 billion and a price-to-earnings ratio of -30.51.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The company had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. On average, research analysts anticipate that Aktis Oncology will post -1.76 EPS for the current year.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the transaction, the director directly owned 3,506 shares of the company’s stock, valued at $86,107.36. This trade represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.30% of the company’s stock.

Institutional Trading of Aktis Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in shares of Aktis Oncology during the 2nd quarter valued at $32,000. Susquehanna International Group LLP bought a new position in shares of Aktis Oncology during the second quarter worth $278,000. Deutsche Bank AG increased its holdings in shares of Aktis Oncology by 49.3% in the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after acquiring an additional 6,942 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in Aktis Oncology during the 2nd quarter worth approximately $1,406,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Aktis Oncology by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock worth $1,548,000 after purchasing an additional 1,051 shares during the period. 28.84% of the stock is currently owned by institutional investors and hedge funds.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.